Run by Roger Perlmutter and backed by more than $1 billion in private funding, Eikon will use the IPO proceeds to advance a ...
By Arasu Kannagi Basil Jan 28 (Reuters) - Eikon Therapeutics, headed by Merck veteran Roger Perlmutter, is targeting a valuation of up to $908.2 million in its initial public offering in the United ...
The integration covers all real-time market data, news, research and other content available on Thomson Reuters’ Eikon terminal product, as well as macroeconomic and cross-asset financial time-series ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results